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Introduction: Leptomeningeal metastases are occurring at higher frequency in cancer patients. The prognosis of
leptomeningeal metastases is poor and standard treatment, which includes radiotherapy and chemotherapy, is
mostly ineffective. Melanoma represents one of the tumors with the highest incidence of leptomeningeal
metastases. For such a disease, the BRAF inhibitors have recently been demonstrated to be effective on melanoma
brain metastases harboring the V600EBRAF mutation.
Case presentation: We report a case of a 39-year-old Italian woman with advanced melanoma with brain, lung
and peritoneum metastases harboring the V600EBRAF mutation. In August 2010 she was enrolled into the BRIM3 trial
and after the randomization process she received dacarbazine. After two cycles, there was evidence of disease
progression in her peritoneum and lung. For this reason, she was enrolled into another clinical trial with the
GSK2118436 BRAF inhibitor, dabrafenib, as a second line of therapy. She had a partial response that was maintained
until 13 weeks of treatment. In January 2011 she developed symptoms typical for brain metastases and received a
diagnosis of leptomeningeal involvement of melanoma cells after an examination of her cerebral spinal fluid;
magnetic resonance imaging was negative for meningitis or brain metastases. Analysis of her cerebral spinal fluid
sample confirmed that the melanoma cells still carried the V600EBRAF mutation. After a few days, our patient went
into a coma and died.
Conclusion: Starting with a clinical case, we discuss the pathogenesis of leptomeningeal metastases and whether
the leptomeninges may represent a sanctuary where melanoma cells may generate resistance and/or BRAF
inhibitors cannot reach an adequate concentration for significant activity. We assess whether treatment with BRAF
inhibitors in melanoma patients should be interrupted as soon as disease progression appears or continued beyond
progression, through the administration of additional compounds.Introduction
The incidence of leptomeningeal metastases (LM) in
cancer patients has increased, probably due to the
achievement of prolonged survival. Both solid tumors
(including breast, lung and gastrointestinal carcinomas
as well as melanoma) and hematopoietic tumors (includ-
ing lymphoma and leukemia) may induce LM formation* Correspondence: paolo.ascierto@gmail.com
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reproduction in any medium, provided the or[1]. The prognosis is poor and less than 10% of patients
survive to 12 months [1,2]. The base of the brain and
the cauda equina are the most prevalent sites of metas-
tasis. Standard treatment, which includes radiotherapy
to symptomatic sites and intrathecal chemotherapy, is
mostly ineffective [3].
Recently, two important compounds changed the his-
tory of treatment for advanced melanoma: the anti- cyto-
toxic T-lymphocyte antigen 4 (CTLA4) monoclonal
antibody [4,5] among unselected patients and the BRAF
inhibitors (BRAFi) [6] among patients carrying a mutation
at the valine 600 codon in the BRAF gene (V600EBRAF mu-
tation). Although both seem to act on melanoma brainal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dabrafenib) seem to be particularly effective on melanoma
brain metastases harboring the V600EBRAF mutation -
which represents the most prevalent oncogenic variant in
such a gene [7-9]. Moreover, a high concordance for
V600EBRAF mutation frequency between primary melano-
mas and correspondent brain metastases from the same
patients has been recently reported by our group [10]. To
date, two important studies are focusing on the treatment
of melanoma brain metastases with BRAFi [11,12].
Here, we report the clinical case of a woman who
developed LM disease during BRAFi treatment and dis-
cuss more general considerations about melanoma brain
involvement.
Case presentation
A 39-year-old Italian woman, who received the diagnosis
of cutaneous melanoma in 2005, was enrolled into the
BRIM3 trial (vemurafenib versus dacarbazine [6]) in Au-
gust 2010 after disease progression was ascertained with
the detection of metastases in both her lung and periton-
eum. Despite being positive for the V600EBRAF mutation,
she was randomized to receive dacarbazine. After two
cycles, disease progression was registered, with the appear-
ance of new peritoneal lesions associated with ascites and
lung lesions associated with pleural effusion. Therefore,
our patient was enrolled into another clinical trial with
GSK2118436 BRAF inhibitor, dabrafenib, as a second line
of therapy. After two weeks of treatment, the ascites and
pleural effusion disappeared and her visceral lesions also
reduced dramatically (Figure 1); this partial response was
maintained over 13 weeks of treatment until the beginning
of January 2011 (Figure 2), when a diagnosis of leptomen-
ingeal involvement of the melanoma cells was inferred by
a cerebral spinal fluid (CSF) examination - with magnetic
resonance imaging negative for meningitis or brain metas-
tases (Figure 3). Analysis of her CSF sample confirmed
that the melanoma cells still carried the V600EBRAF muta-
tion (not shown). After a few days, our patient went into a
coma and died.
Discussion
To the best of our knowledge, there are no data available
for the use of BRAFi in controlling LM from melanoma.
The only clinical evidence provided for such types of
drugs has been regarding their effectiveness on brain
metastases [7-9]. Although unknown, the effect of
BRAFi on LM may be due to different molecular
mechanisms. Preclinical studies on such lesions showed
the involvement of at least two important processes:
angiogenesis and proliferation [13-18].
Reijneveld et al. demonstrated that neovascularization
is important for the growth of LM in mice and in
humans [13]. Systemic targeting of the vascularcompartment may be a useful approach in novel thera-
peutic strategies for patients with LM. The identification
of selective receptors on brain capillary endothelium and
tumor cells, which facilitate tumor cell adhesion and
metastasis formation at restricted sites, may represent
an important therapeutic target. In particular, Brandsma
et al. have indicated the potential importance of integrin
expression by demonstrating that constitutive integrin
activation on leukemic cells contributed to leptomenin-
geal leukemia [14]. In that case, authors attributed such
findings to an increased integrin-mediated leukemic cell
adhesion to the leptomeninges, which mostly involved
β3 integrin as determined by in vitro assays on primary
leptomeningeal cell layers [14]. The Ras-related guano-
sine triphosphatase protein, Rap-1, a protein that has
been shown to be a key regulator of integrin activation
in leukocytes, may be another interesting candidate [15-
17]. This research could lead to the development of
agents that efficiently block tumor cell adhesion in order
to prevent LM progression. Küsters-Vandevelde et al.
investigated the expression of activating mutations of
the GNAQ gene in primary melanocytic tumors of the
central nervous system (CNS) as well as the mutation
status of BRAF, NRAS and HRAS genes on LM [18]. The
GNAQ mutations were found in uveal melanoma and
primary melanocytic lesions of the CNS (mutations in
codon 209 of GNAQ form an alternative route to
mitogen-activated protein kinase (MAPK) activation),
while mutations of NRAS and BRAF were detected in
metastatic lesions of the CNS, including LM (no involve-
ment of HRAS was observed) [18]. Our data indicated a
frequency of 48% for cerebral V600BRAF mutations, with
a quite similar incidence rate of such BRAF variants
among primary melanomas and corresponding brain
metastases from the same patients [10]. This suggests
that melanoma cells are unlikely to change their BRAF
mutational status during the formation of brain metasta-
sis. As a consequence, inhibitors of mutated BRAF are
postulated to represent a therapeutic approach in LM
from melanoma.
Despite indications that inhibitors of mutated BRAF may
represent an effective therapeutic approach in melanoma
brain metastases, our patient in this case showed respon-
siveness on visceral sites but dramatic disease progression
to the leptomeninges during therapy with BRAFi.
From the biological point of view, this is consistent
with the hypothesis that acquired resistance to BRAF in-
hibition may depend on the activation of alternative sur-
vival pathways, with no modification of the BRAF
mutational status [19-24]. In particular, a large variety of
induced alterations has been indicated to drive resist-
ance to BRAFi. These include upregulation of the recep-
tor tyrosine kinase effectors or activating alterations of
NRAS or PDGFRβ genes [19]; switching among the three
Figure 1 Positron emission tomography scan evaluation. (A and C) At baseline; (B and D) after 15 days.
Figure 2 Computed tomography scan evaluation. (A) Baseline: great metastatic nodular lesion on the left lung (white arrow). (B) Baseline:
lung parenchymal windows showing the great lesion on the left and a drainage tube for thoracentesis with residual pneumothorax (white
arrow). (C) Week 12 under treatment: reduction of the great lung lesion with small residual nodule (white arrow).
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Figure 3 Liquor sample evaluation. (A) Hematoxylin and eosin staining; (B) HMB45 immunocytochemistry; (C) S100 immunocytochemistry.
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CRAF protein [20]; amplification of the CCND1/Cyclin
D1 gene or lack of phosphatase-and-tensin homologue
function [21]; or mutations in the downstream gene for
methyl ethyl ketone (MEK) [22]. Recently, two additional
mechanisms of resistance to BRAFi have been described:
activation of the MAP3K8 gene, which encodes the COT
MAPK pathway agonist (COT is able to activate down-
stream extracellular signal-regulated kinase protein
through a MEK-dependent mechanism not requiring
RAF-driven signals) [23], and induction of the alterna-
tive BRAF-independent insulin growth factor receptor 1-
phosphatidylinositol-3-kinase (PI3K) signaling pathway
with increased intracellular levels of the downstream
Akt effector [24]. Nevertheless, although the leptomen-
inges may represent a special ‘sanctuary’ site for the de-
velopment of resistance, a combination of response and
resistance in specific sites as well as a sequential occur-
rence of an initial response and later tumor growth
within metastases in the setting of BRAFi should be
carefully taken into account.
From the clinical point of view, these findings open
the discussion as to whether treatment with BRAFi
should be interrupted as soon as progression appears or
if a different treatment should be added to BRAFi-based
therapy. Recently, a study indicated that the control of
disease progression is not necessarily rapid under BRAFi
treatment and, in a subset of patients with disease pro-
gression, continuation of treatment with BRAFi may be
potentially beneficial [25]. These authors suggested the
need for further study to evaluate the impact of post-
progression treatment with the BRAFi [25]. In cases of a
mixed response (complete or partial response in some
lesions associated with progression in other sites), we
propose that therapy with BRAFi should be continued
and treatment with a new agent (for example, a MEK in-
hibitor, PI3K inhibitor or anti-CTLA4) should be added.This combination approach will surely represent the
standard therapeutic strategy in the future [26]. Recently,
a phase I study based on indications derived from pre-
clinical models suggested that an upfront combination
therapy, instead of a sequential administration of tar-
geted compounds, may act as a very promising approach
toward the reduction of the time to resistance [27].
In our case, we demonstrated that the V600EBRAF mu-
tation was still present in melanoma cells from our
patient’s CSF. This could indicate that the disease pro-
gression to leptomeninges was due to the development
of drug resistance in BRAF mutated cells (for example,
through a switch to the CRAF signaling pathway) and
not to the appearance of a different melanoma brain
clone.
Conclusions
The occurrence of LM has to be considered as a possible
event during treatment with BRAFi in patients with mel-
anoma. Although further studies based on more appropri-
ate samplings from patients with meningeal metastases
are awaited, the existence of alternative or resistance
mechanisms that may be activated in response to the in-
hibition of the BRAF-driven pathway represents a clear in-
dication that a combination of targeted compounds
should be planned for the treatment of melanoma beyond
disease progression.
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